Alkermes
alkermes inhibitor portfolio introduction to and synaptic dysfunction biological rationale for the program established epigenetic control of synapse formation and function modulated by inhibitors limitations of first generation agents as therapeutics alkermes novel rationally designed to selectively target the complex first nominated development candidate from inhibitor portfolio leveraging proprietary chemistry and insight to other potential compounds and indications including frontotemporal dementia with precursor mutations histone repressor of repressor element silencing transcription factor | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
112 of 144
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io